Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

View Full Paper
Ask AI
Bookmark
Share

Authors

CFC. FreitasHospital de São JoãoARAkhil RajendraUniversity Health NetworkMDMarta DavidsonUniversity Health Network

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows front-line azacitidine plus venetoclax worsens outcomes in AML patients achieving morphologic leukemia-free state, suggesting need for improved strategies.

Key Points

  • This research aims to explore the effects of morphologic leukemia-free state on survival outcomes in AML patients treated with azacitidine and venetoclax.
  • Conducted a retrospective study at Princess Margaret Cancer Centre from 2017 to 2024.
  • Included patients diagnosed with AML receiving front-line azacitidine plus venetoclax treatment.
  • Categorized responses based on ELN recommendations and analyzed primary outcomes of overall survival.
  • Among 132 reviewed patients, 70% achieved morphologic composite remission with 20% reaching morphologic leukemia-free state.
  • Patients achieving MLFS had a median overall survival of 6.6 months compared to 22.5 months for those achieving complete remission.
  • No significant difference in measurable residual disease positivity between MLFS and complete remission cohorts.

Cite This Study

Freitas et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da20https://doi.org/10.1182/blood-2025-3508
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world clinical outcomes of newly diagnosed AML unfit for intensive chemotherapy treated with venetoclax and azacitidine: does it depend on the number of days of venetoclax administration?2026
  2. 2A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes2025 · 1 citations
  3. 3Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia2025 · 33 citations
  4. 4Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China2026
  5. 5Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience2025